Compare Nuwellis Inc (NUWE) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs UnitedHealth Group Inc — how do they compare? Nuwellis Inc trades at $1.28 (market cap $515.48K), while UnitedHealth Group Inc trades at $401.9 (market cap $364.06B). The key difference: UnitedHealth Group Inc is far larger — about 706254.4× Nuwellis Inc's market cap, and UnitedHealth Group Inc pays a 2.29% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| NUWE | UNH | |
|---|---|---|
Market Cap | $515.48K | $364.06B |
Sector | Technology | Health |
52-Week High | $220.50 | $436.35 |
52-Week Low | $1.41 | $259.02 |
Enterprise Value | -$1.29M | $405.92B |
Dividend Yield | — | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $1.41, down 0.7% today, with a bearish technical signal despite oversold RSI readings. The company reported a net loss of $17.52 million on $8.27 million revenue in 2025, with negative cash flow from operations. Recent news highlights expansion in pediatric care and a $3.4 million direct offering in July 2026, alongside a reverse stock split executed in June 2026.
Outlook remains challenged by persistent losses and high cash burn, though revenue growth and product development offer potential. Risks include reliance on financing and competitive pressures. Analyst consensus is split evenly between Buy and Hold, reflecting cautious optimism amid fundamental weaknesses.
UnitedHealth Group (UNH) trades at $402.19, down 1.6% with bearish technical signals despite strong fundamental performance. The company reported three consecutive quarterly earnings beats with Q1 2026 EPS of $7.23 beating estimates by 12%. Revenue grew to $447.57 billion in 2025, though net margins compressed to 2.69%. Analyst consensus remains strongly bullish with 83% buy ratings and a $476.50 price target representing 18% upside potential.
UNH presents a compelling long-term investment opportunity driven by aging demographics and healthcare digitization, but faces near-term headwinds from regulatory scrutiny and margin pressure. The stock's current valuation at 25.85x P/E appears reasonable given growth prospects, though investors should monitor legal challenges and Medicare reimbursement trends that could impact profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
